Literature DB >> 7520855

Treatment of oral Candida mucositis infections.

G E Garber1.   

Abstract

Infections due to Candida spp. are increasing in incidence as the number of immune compromised patients increases. The common presentation of Candida mucositis and oral infections includes atrophic candidiasis, angular cheilitis, leukoplakia and oesophagitis. An increasing spectrum of antifungal agents, including imidazoles, are available for treatment and suppression of this common infection. In chronically immune-compromised patients such as those with severe HIV related immune deficiency, eradication of the infection may not be possible. This requires a stepwise approach to management and may require the use of potent, toxic agents such as amphotericin B to suppress the symptoms and signs of infection sufficiently to provide the patient with symptomatic relief. Resistant organisms are also becoming a greater problem in this patient population.

Entities:  

Mesh:

Year:  1994        PMID: 7520855     DOI: 10.2165/00003495-199447050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus.

Authors:  S L Koletar; J A Russell; R J Fass; J F Plouffe
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV.

Authors:  D E Smith; J Midgley; M Allan; G M Connolly; B G Gazzard
Journal:  AIDS       Date:  1991-11       Impact factor: 4.177

3.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

Review 4.  Fluconazole: a new antifungal agent.

Authors:  S F Kowalsky; D M Dixon
Journal:  Clin Pharm       Date:  1991-03

5.  Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial.

Authors:  E A Petersen; D W Alling; C H Kirkpatrick
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

6.  Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study.

Authors:  D J Marriott; P D Jones; J F Hoy; B R Speed; J L Harkness
Journal:  Med J Aust       Date:  1993-03-01       Impact factor: 7.738

7.  The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients.

Authors:  M Bonacini; T Young; L Laine
Journal:  Arch Intern Med       Date:  1991-08

8.  Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment.

Authors:  D H Shepp; A Klosterman; M S Siegel; J D Meyers
Journal:  J Infect Dis       Date:  1985-12       Impact factor: 5.226

9.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).

Authors:  G Lake-Bakaar; W Tom; D Lake-Bakaar; N Gupta; S Beidas; M Elsakr; E Straus
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

10.  Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial.

Authors:  L Laine; R H Dretler; C N Conteas; C Tuazon; F M Koster; F Sattler; K Squires; M Z Islam
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

View more
  7 in total

1.  Interactions between host and oral commensal microorganisms are key events in health and disease status.

Authors:  Mahmoud Rouabhia
Journal:  Can J Infect Dis       Date:  2002-01

Review 2.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 3.  Oral candidiasis.

Authors:  A Akpan; R Morgan
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

4.  The association of Candida and antifungal therapy with pro-inflammatory cytokines in oral leukoplakia.

Authors:  Shalini R Gupta; Nidhi Gupta; Alpana Sharma; Immaculata Xess; Gagandeep Singh; Kalaivani Mani
Journal:  Clin Oral Investig       Date:  2021-04-04       Impact factor: 3.573

5.  Candida albicans Adherence to Glass Ionomer Restorative Dental Material.

Authors:  Shirin Lawaf; Arash Azizi
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2009-06-05

6.  Prevalence of Candida species in the oral cavity of patients undergoing head and neck radiotherapy.

Authors:  Arash Azizi; Masood Rezaei
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2009-09-16

7.  Influence of fixed orthodontic appliances on the change in oral Candida strains among adolescents.

Authors:  Yan Zheng; Zhenya Li; Xiangyi He
Journal:  J Dent Sci       Date:  2014-05-14       Impact factor: 2.080

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.